异甘草酸镁治疗乙型肝炎肝硬化的临床观察

Clinical Observation of Magnesium Isoglycyrrhizinate in Treatment of HBV-Related Liver Cirrhosis

目的:观察异甘草酸镁对于乙型肝炎肝硬化患者的临床应用优势。方法:将65例乙型肝炎肝硬化患者,随机分为治疗组(33例)和对照组(32例),分别给予异甘草酸镁和甘草酸二铵常规治疗,疗程14天,比较治疗前后谷丙转氨酶(ALT)、谷草转氨酶(AST)、Na+、K+、腹围、白蛋白使用量的变化情况。结果:1)组间治疗后比较,治疗组ALT、AST水平降低更显著,差异有统计学意义(P +、K+浓度均无显著性差异(P >0.05);3) 组间比较,治疗组腹围降低更显著,差异有统计学意义(P 0.05)。结论:异甘草酸镁对乙型肝炎肝硬化患者,具有较好的保肝作用,可以维持腹围的稳定,改善病人的生活质量。

Objective: To evaluate the therapeutic efficacy of magnesium isoglycyrrhizinate (MIG) in treatment of HBV-related d liver cirrhosis. Methods: Sixty-five HBV-related liver cirrhosis patients were assigned to two groups by using a random number table: MIG treatment group (n = 33), and control group treated with Diammonium Glycyrrhizinate (n = 32). In all cases, the treatment course was 14 days. Alanine transaminase (ALT), aspartate aminotransferase (AST), Na+, K+, abdominal circumference, used amount of albumin were evaluated in both groups before and after treatment. Results: 1) After treatment, the reducing of ALT, AST was significant different between groups (P +, K+ was not significant different between groups (P >0.05). 3) After treatment, abdominal circumference was significant different between groups (P 0.05). Conclusion: MIG has a good therapeutic effect in treatment of HBV-related liver cirrhosis with improvement of liver function, abdominal circumference and the patient’s life quality.